 - Inhibition of hyperactive RAS network signaling is nine times more effective with gedatolisib than with a PI3K-α inhibitor - - Synergistic cooperation between PI3KmTOR and BCL signaling detected, suggesting potential patient benefit of combining gedatolisib with a BCL inhibitor - MINNEAPOLIS, MN ACCESSWIRE April 12, 2021 Celcuity Inc. NASDAQ:CELC, a clinical-stage biotechnology company pursuing an integrated companion diagnostic CDx and therapeutic strategy for treating patients with cancer, presented results of studies evaluating gedatolisib a pan-PI3KmTOR inhibitor, inavolisib a PI3K-α inhibitor, and navitoclax a BCL inhibitor in breast and ovarian patient tumors. Results were presented in two e-posters at the American Association for Cancer Research AACR Annual Meeting. 